A 24-week, single-arm study to evaluate the pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2015
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV infections
- Focus Pharmacokinetics; Therapeutic Use
- 30 Nov 2015 New trial record